| Literature DB >> 32546177 |
Silvia Raphaelis1, Florian Frommlet2, Hanna Mayer1, Antje Koller3,4.
Abstract
BACKGROUND: Pain self-management support interventions were effective in controlled clinical trials and meta analyses. However, implementation of these complex interventions may not translate into identical effects. This paper evaluates the implementation of ANtiPain, a cancer pain self-management support intervention in routine clinical practice according to the Reach Efficacy-Adoption Implementation Maintenance framework.Entities:
Keywords: Neoplasms; Oncology nursing; Pain; Patient education as topic; Randomized controlled trials; Self-management
Year: 2020 PMID: 32546177 PMCID: PMC7296932 DOI: 10.1186/s12885-020-06729-0
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Fig. 1Stepped wedge plan and recruitment during 17-months study period. 1the columns represent the study periods of the stepped wedge study, one study period was 24 days (data collection from Jan 2017 to May 2018). 2During the summer, recruitment was paused for two periods. 3H: hospital; H1 shaded dark grey, H2 shaded lighter grey, H3 shaded lightest grey; the order of the implementation was randomized over all three settings. 4Number of recruited patients in the respective cell (time period on the respective ward). 5Date of actual ANtiPain training for intervention nurses on respective ward, steps were planned every 24 days. 6Shaded areas indicate that no patient was recruited on that ward during that time
Participating hospitals and wards and recruitment (ITT [PP])
| Hospital | Ward | Order | Main medical field | % oncology patients | size | N IG ITT (PP) | N CG ITT (PP) |
|---|---|---|---|---|---|---|---|
| H 1 | W 9f | 8 | Gynecology | 40 | 25 | 0 | 3 |
| H 1 | W 10 | 3 | Oncology/Internal medicine | 70 | 21 | 3 | 1 |
| H 1 | W 11 | 14 | Internal Medicine/Oncology | 40 | 20 | 0 | 6 |
| H 1 | W 12 | 1 | Pneumology | 45 | 22 | 3 | 1 |
| H 1 | W 13 | 12 | Pneumology | 40 | 21 | 0 | 1 |
| H 2 | W 14 | 17 | Internal Medicine/Oncology | 60 | 27 | 0 | 5 |
| H 2 | W 15 | 9 | Internal Medicine/Oncology | 50 | 27 | 0 | 3 |
| H 2 | W 16 | 10 | Internal Medicine/Oncology | 50 | 27 | 0 | 5 |
| H 2 | W 17 | 2 | Oncology/Hematology | 98 | 13 | 4 (3) | 2 (3) |
| H 3 | W 1 | 15 | Surgery | 2g | 32 | 0 | 1 |
| H 3 | W 2 | 5 | Surgery | 70 | 23 | 9 | 4 |
| H 3 | W 3 | 16 | Oncology | 99 | 25 | 0 | 17 |
| H 3 | W 4 | 11 | Gynecology | 95 | 20 | 8 (6) | 21 (23) |
| H 3 | W 5 | 13 | Ear nose and throat | 30 | 24 | 1 | 3 |
| H 3 | W 6 | 6 | Ear nose and throat | 30 | 24 | 0 | 6 |
| H 3 | W 7 | 7 | Radiotherapy | 98 | 36 | 16 (11) | 9 (14) |
| H 3 | W 8 | 4 | Radiotherapy | 99 | 12 | 17 (9) | 4 (12) |
aOrder of implementation, each step/sequence between implementations was ~ 24 days
bThis assumed rate was assessed in an interview with head nurses prior to recruitment of each ward
cNumber of beds
dIG: intervention group, ITT: intention to treat approach - analyzing each patient after implementation of the intervention (PP: per protocol approach - analyzing each patient who received the intervention n in brackets)
eCG: control group, ITT: intention to treat approach - analyzing each patient before implementation of the intervention (PP: per protocol approach - analyzing each patient who did not receive the intervention n in brackets)
fAfter recruitment and randomization, an organizational change caused that this ward did not have many oncology patients any more. At inclusion, this ward would have had 50% oncology patients
Fig. 2Flow of participants during study
Demographic and clinical characteristics of participants
| Control group ( | Intervention group ( | |
|---|---|---|
| age | ||
| Mean (median); percentile 25/75 | 58.9 (60.0); 49/73 | 58.6 (59.0); 52/68 |
| Gender; % (n) | ||
| male | 43 (40) | 49 (30) |
| female | 57 (52) | 51 (31) |
| Live alone in household; % (n) | ||
| yes | 35 (32) | 36 (22) |
| School education; % (n) | ||
| Basic school education | 7 (6) | 17 (10) |
| Higher school education/job training | 78 (71) | 67 (40) |
| University education | 15 (14) | 17 (10) |
| Months since diagnosis | ||
| Mean (median); percentile 25/75 | 27.4 (6.0); 2/31 | 17.4 (3.0); 1/11 |
| Diagnosis; % (n) | ||
| Gynecological | 24 (22) | 16 (10) |
| Gastrointestinal | 22 (20) | 20 (12) |
| Ear nose and throat | 13 (12) | 23 (14) |
| LungCa | 11 (10) | 15 (9) |
| Hematological | 7 (6) | 3 (2) |
| BoneCa | 7 (6) | 2 (1) |
| BreastCa | 5 (5) | 8 (5) |
| Other (prostate, skin, thoracic, etc) | 10 (9) | 13 (8) |
| Missing | 2 (2) | 0 |
| Painduration in months | ||
| Mean (median); percentile 25/75 | 20.6 (2.0); 1/9 | 5.0 (2.0); 0/5 |
| Pain pattern; % (n) | ||
| Constant pain, minor fluctuations | 34 (31) | 25 (15) |
| Constant pain, major fluctuations | 33 (30) | 41 (24) |
| No constant pain but pain attacks | 32 (29) | 34 (20) |
| Performance status (ECOG) | ||
| Mean (median); Percentile 25/75 | 2.4 (3.0); 2/3 | 2.2 (2.0); 2/3 |
| PHQ-2 | ||
| Mean (median); Percentile 25/75 | 2.9 (3.0); 2/4 | 2.6 (2.5); 2/4 |
| Questionnaires completed; % (n)a | ||
| Baseline only | 20 (18) | 15 (9) |
| Baseline and T2b | 70 (64) | 74 (45) |
| Complete datasets | 59 (54) | 57 (35) |
| BPI pain interference total score T0 | ||
| Mean (median); Percentile 25/75 | 5.6 (6); 4/7 | 5.0 (5); 4/6 |
| BPI worst pain T0 | ||
| Mean (median); Percentile 25/75 | 7.9 (8.0); 7/9 | 7.1 (7.5); 5.5/9 |
| BPI average pain T0 | ||
| Mean (median); Percentile 25/75 | 5.9 (6); 5/7 | 5.2 (5.0); 4/6.5 |
| BQIIG12 T0 | ||
| Mean (median); Percentile 25/75 | 2.1 (2); 1.5/3 | 2.1 (2); 1/2.5 |
| FESS total score T0 | ||
| Mean (median); Percentile 25/75 | 2.4 (2); 1.5/3 | 2.2 (2); 1/3 |
| Health status T0 | ||
| Mean (median); Percentiles 25/75 | 3.0 (3); 2/4 | 2.9 (3); 2/4 |
| Quality of life T0 | ||
| Mean (median); Percentiles 25/75 | 3.1 (3); 2/4 | 2.8 (3); 2/3 |
| Analgesic medication; % (n)c | ||
| No analgesics | 2 (2) | 2 (1) |
| Non-opioids | 23 (21) | 20 (12) |
| Weak opioids | 6 (5) | 30 (18) |
| Strong opioids | 69 (63) | 48 (29) |
| Co-Analgesics; % (n) | ||
| yes | 28 (25) | 17 (10) |
| Medication schedule; % (n) | ||
| No pain medication | 2 (2) | 0 |
| Fixed and as needed analgesics | 77 (70) | 82 (49) |
| Only fixed scheduled analgesic | 14 (13) | 13 (8) |
| Only as needed analgesics | 7 (6) | 5 (3) |
| Daily morphine equivalent | ||
| Mean (median); Percentile 25/75 | 62.3 (40); 0/94 | 43.8 (20); 0/63 |
| Inadequate analgesia according to PMI; % (n)d | ||
| yes | 26 (23) | 20 (12) |
Abbreviations: BPI brief pain inventory, BQIIG12 Barriers questionnaire II German - short version, FESS Pain related self-efficacy score-German, ECOG Eastern Co-operative Oncology Group performance status, PHQ-2 patient health questionnaire (2-item version)
aPercentages do not sum up to 100 because of overlap between the categories; b T2 was measured 4 weeks after discharge and is the primary measurement time point;); c according to the WHO step ladder; d A negative pain management Index indicates inadequate pain
Fig. 3Regression lines of pain interference with daily activities (time in weeks). Each line represents the regression line of one ward per recruitment period. The light blue lines belong to the 9 wards that did not provide any patients in the intervention period. Line thickness represents the number of patients for the respective ward
Fig. 4Line diagrams on original scale of secondary outcomes
Effect sizes of primary and secondary endpoints (intention to treat approach)
| Outcome | Cohen’s d T1 | Cohen’s da T2 | Cohen’s d T3 |
|---|---|---|---|
| Pain interference with daily activitiesb | .12 | −.21 | −.29 |
| Pain interference with daily activities wards with IGb | −.21 | −.59 | −.54 |
| Average painb | .26 | −.04 | −.11 |
| Average pain wards with IGb | .02 | −.27 | −.32 |
| Maximum painb | .12 | −.02 | −.05 |
| Maximum pain wards with IGb | .08 | −.26 | −.23 |
| Barriers towards pain management (BQII-G12)b | −.30 | −.34 | −.46 |
| Barriers towards pain management with IGb | −.33 | −.31 | −.55 |
| Pain-related self-efficacy (FESS)c | .25 | .17 | .53 |
| Pain-related self-efficacy wards with IGc | .57 | .48 | .72 |
| EORTC health status generic questionc | .16 | .26 | .37 |
| EORTC health status generic question with IGc | .18 | .28 | .48 |
| EORTC health-related quality of life generic questionc | .32 | .20 | .27 |
| EORTC health-related quality of life generic question with IGc | .47 | .24 | .48 |
| Patient satisfaction with pain self-management supportc | .61 | nm | nm |
| Patient satisfaction with pain self-management support wards with IGc | .65 | nm | nm |
| Patient satisfaction with pain managementc | .46 | nm | nm |
| Patient satisfaction with pain management wards with IGc | .62 | nm | nm |
T1: 2 weeks after discharge; T2: 4 weeks after discharge (primary endpoint printed bold); T3: 8 weeks after discharge; IG: Intervention group; wards with IG: Ward 2, 4, 5, 7, 8, 10, 12 and 17; nm: not measured;
aCohen’s d: .2 < d < .5 small effect, .5 ≤ d < .8 moderate effect, d ≥ .8 large effect; b Reduction (negative d) desired; c Rise (positive d) desired;